MAIA BIOTECHNOLOGY INC (MAIA) Stock News

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024

MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024.

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024

MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024.

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology Announces $2.44 Million Private Placement

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six patients continuing treatment beyond 12 months.

Mentions: REGN

Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Mentions: LIFW FEIM MIRA STEM ...

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at the BIO International Convention 2024

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

MAIA Biotechnology Announces $1.00 Million Private Placement